SEARCH:   Advanced

Blood, 1 April 2004, Vol. 103, No. 7, pp. 2474-2479. Prepublished online as a Blood First Edition Paper on November 26, 2003; DOI 10.1182/blood-2003-09-3080. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-09-3080v1 103/7/2474    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gallamini, A. Articles by Federico, M. Search for Related Content PubMed PubMed Citation Articles by Gallamini, A. Articles by Federico, M. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study Andrea Gallamini, Caterina Stelitano, Roberta Calvi, Monica Bellei, Daniele Mattei, Umberto Vitolo, Fortunato Morabito, Maurizio Martelli, Ercole Brusamolino, Emilio Iannitto, Francesco Zaja, Sergio Cortelazzo, Luigi Rigacci, Liliana Devizzi, Giuseppe Todeschini, Gino Santini, Maura Brugiatelli, and Massimo Federico, for the Intergruppo Italiano Linfomi From the Struttura Complessa (S.C.) Ematologia, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy; Divisione di Ematologia, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy; Cattedra di Oncologia Medica, Università di Modena e Reggio Emilia, Modena, Italy; S.C. Ematologia, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy; Centro Trapianti Midollo Osseo, Azienda Osp. Bianchi-Melacrino-Morelli, Reggio Calabria, Italy; Divisione di Ematologia, IRCCS Policlinico S. Matteo-Pavia, Italy; Dipartimento di Oncologia, Unità di Ematologia e TMO, Università di Palermo, Palermo, Italy; Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Roma, Italy; Clinica Ematologica, Dip. to Ricerche Mediche e Morfologiche, Policlinico Università, Udine, Italy; Divisione di Ematologia, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Cattedra e Divisione di Ematologia, Padiglione S. Luca, Policlinico Careggi, Firenze, Italy; Divisione di Oncologia Medica C, Istituto Nazionale Tumori, Milano, Italy; Cattedra di Ematologia, Università di Verona, Verona, Italy; Divisione di Ematologia, Azienda Ospedaliera Ospedale S. Martino, Genova, Italy; and Divisione di Ematologia, Azienda Ospedaliera Papardo, Messina, Italy. To assess the prognosis of peripheral T-cell lymphoma unspecified, we retrospectively analyzed 385 cases fulfilling the criteria defined by the World Health Organization classification. Factors associated with a worse overall survival (OS) in a univariate analysis were age older than 60 years (P = .0002), equal to or more than 2 extranodal sites (P = .0002), lactic dehydrogenase (LDH) value at normal levels or above (P < .0001), performance status (PS) equal to or more than 2 (P .0001), stage III or higher (P = .0001), and bone marrow involvement (P = .0001). Multivariate analysis showed that age (relative risk, 1.732; 95% CI, 1.300-2.309; P < .0001), PS (relative risk, 1.719; 95% CI, 1.269-2.327, P < .0001), LDH level (relative risk, 1.905; 95% CI, 1.415-2.564; P < .0001), and bone marrow involvement (relative risk, 1.454; 95% CI, 1.045-2.023; P = .026) were factors independently predictive for survival. Using these 4 variables we constructed a new prognostic model that singled out 4 groups at different risk: group 1, no adverse factors, with 5-year and 10-year OS of 62.3% and 54.9%, respectively; group 2, one factor, with a 5-year and 10-year OS of 52.9% and 38.8%, respectively; group 3, 2 factors, with 5-year and 10-year OS of 32.9% and 18.0%, respectively; group 4, 3 or 4 factors, with a 5-year and 10-year OS of 18.3 and 12.6%, respectively (P .0001; log-rank, 66.79). CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. J. Savage, N. L. Harris, J. M. Vose, F. Ullrich, E. S. Jaffe, J. M. Connors, L. Rimsza, S. A. Pileri, M. Chhanabhai, R. D. Gascoyne, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project Blood, June 15, 2008; 111(12): 5496 - 5504. [Abstract] [Full Text] [PDF] S. Le Gouill, N. Milpied, A. Buzyn, R. Peffault De Latour, J.-P. Vernant, M. Mohty, M.-P. Moles, K. Bouabdallah, C.-E. Bulabois, J. Dupuis, et al. Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire J. Clin. Oncol., May 10, 2008; 26(14): 2264 - 2271. [Abstract] [Full Text] [PDF] S. Mercadal, J. Briones, B. Xicoy, C. Pedro, L. Escoda, C. Estany, M. Camos, L. Colomo, I. Espinosa, S. Martinez, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma Ann. Onc., May 1, 2008; 19(5): 958 - 963. [Abstract] [Full Text] [PDF] N. Mourad, N. Mounier, J. Briere, E. Raffoux, A. Delmer, A. Feller, C. J. L. M. Meijer, J.-F. Emile, R. Bouabdallah, A. Bosly, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood, May 1, 2008; 111(9): 4463 - 4470. [Abstract] [Full Text] [PDF] K. Tsukasaki, A. Utsunomiya, H. Fukuda, T. Shibata, T. Fukushima, Y. Takatsuka, S. Ikeda, M. Masuda, H. Nagoshi, R. Ueda, et al. VCAP-AMP-VECP Compared With Biweekly CHOP for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study JCOG9801 J. Clin. Oncol., December 1, 2007; 25(34): 5458 - 5464. [Abstract] [Full Text] [PDF] A. Gallamini, F. Zaja, C. Patti, A. Billio, M. R. Specchia, A. Tucci, A. Levis, A. Manna, V. Secondo, L. Rigacci, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial Blood, October 1, 2007; 110(7): 2316 - 2323. [Abstract] [Full Text] [PDF] M. Cuadros, S. S. Dave, E. S. Jaffe, E. Honrado, R. Milne, J. Alves, J. Rodriguez, M. Zajac, J. Benitez, L. M. Staudt, et al. Identification of a Proliferation Signature Related to Survival in Nodal Peripheral T-Cell Lymphomas J. Clin. Oncol., August 1, 2007; 25(22): 3321 - 3329. [Abstract] [Full Text] [PDF] J. Rodriguez, E. Conde, A. Gutierrez, J. J. Lahuerta, R. Arranz, A. Sureda, J. Zuazu, A. F. de Sevilla, M. Bendandi, C. Solano, et al. The adjusted International Prognostic Index and {beta}-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma Haematologica, August 1, 2007; 92(8): 1067 - 1074. [Abstract] [Full Text] [PDF] P. P. Piccaluga, C. Agostinelli, S. Righi, P. L. Zinzani, and S. A. Pileri Expression of CD52 in peripheral T-cell lymphoma Haematologica, April 1, 2007; 92(4): 566 - 567. [Abstract] [Full Text] [PDF] J Rodriguez, E Conde, A Gutierrez, R Arranz, A Leon, J Marin, M Bendandi, C Albo, M. Caballero, and On behalf of the Grupo Espanol de Linfomas/Traspla The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience Ann. Onc., April 1, 2007; 18(4): 652 - 657. [Abstract] [Full Text] [PDF] P. Went, C. Agostinelli, A. Gallamini, P. P. Piccaluga, S. Ascani, E. Sabattini, F. Bacci, B. Falini, T. Motta, M. Paulli, et al. Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score J. Clin. Oncol., June 1, 2006; 24(16): 2472 - 2479. [Abstract] [Full Text] [PDF] L. Pagano, A. Gallamini, G. Trape, L. Fianchi, D. Mattei, G. Todeschini, A. Spadea, S. Cinieri, E. Iannitto, M. Martelli, et al. NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey Ann. Onc., May 1, 2006; 17(5): 794 - 800. [Abstract] [Full Text] [PDF] J. Lee, C. Suh, Y. H. Park, Y. H. Ko, S. M. Bang, J. H. Lee, D. H. Lee, J. Huh, S. Y. Oh, H.-C. Kwon, et al. Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study J. Clin. Oncol., February 1, 2006; 24(4): 612 - 618. [Abstract] [Full Text] [PDF] J. P. Greer Therapy of Peripheral T/NK Neoplasms Hematology, January 1, 2006; 2006(1): 331 - 337. [Abstract] [Full Text] [PDF] J. M. Vose and The International PTCL Project International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: Poor Outcome by Prognostic Indices and Lack of Efficacy with Anthracyclines. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 811 - 811. [Abstract] P. P. Piccaluga, P. Went, C. Agostinelli, A. Gallamini, S. Ascani, E. Sabattini, F. Bacci, B. Falini, T. Motta, M. Paulli, et al. Marker Expression in Peripheral T-Cell Lymphoma Unspecified: Proposal of a Clinical-Pathologic Prognostic Score. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 2819 - 2819. [Abstract] K. J. Savage Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types) Hematology, January 1, 2005; 2005(1): 267 - 277. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020